Concert Pharmaceuticals (CNCE) Short Interest Ratio & Short Volume → This company has increased its dividend every year for 54 years (From DTI) (Ad) Free CNCE Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Short InterestStock Analysis Concert Pharmaceuticals Short Interest DataCurrent Short Volume1,080,000 sharesPrevious Short Volume2,600,000 sharesChange Vs. Previous Month-58.46%Dollar Volume Sold Short$9.02 millionShort Interest Ratio / Days to Cover0.6Last Record DateFebruary 15, 2023Outstanding Shares47,940,000 sharesPercentage of Shares Shorted2.25%Today's Trading Volume0 sharesAverage Trading Volume2,970,800 sharesToday's Volume Vs. Average0% Short Selling Concert Pharmaceuticals ? Sign up to receive the latest short interest report for Concert Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatCNCE Short Interest Over TimeCNCE Days to Cover Over TimeCNCE Percentage of Float Shorted Over Time Ad DarwinYour Next Portfolio Star: Revealing 2024's Top Stock Pick We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)Click here to download your report Concert Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 2/15/20231,080,000 shares $9.02 million -58.5%N/A0.6 $8.35 1/31/20232,600,000 shares $21.68 million +19.8%N/A1.6 $8.34 1/15/20232,170,000 shares $15.30 million -0.9%N/A1.5 $7.05 12/30/20222,190,000 shares $12.79 million +10.1%N/A5 $5.84 12/15/20221,990,000 shares $9.37 million -4.3%N/A4.9 $4.71 11/30/20222,080,000 shares $10.03 million -5.0%N/A4.7 $4.82 Get the Latest News and Ratings for CNCE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Concert Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 11/15/20222,190,000 shares $10.86 million +3.3%N/A4.6 $4.96 10/31/20222,120,000 shares $12.61 million +12.8%N/A4.1 $5.95 10/15/20221,880,000 shares $11.41 million +13.3%N/A3.5 $6.07 9/30/20221,660,000 shares $11.12 million +33.9%N/A3.2 $6.70 9/15/20221,240,000 shares $8.32 million +15.9%N/A2.4 $6.71 8/31/20221,070,000 shares $7.04 million +24.0%N/A1.9 $6.58 8/15/2022863,200 shares $5.97 million -21.5%N/A0.9 $6.92 7/31/20221,100,000 shares $6.16 million No ChangeN/A1.2 $5.60 7/15/20221,100,000 shares $5.29 million +16.5%N/A1.3 $4.81 6/30/2022944,600 shares $3.98 million -10.9%N/A1.2 $4.21 6/15/20221,060,000 shares $4.74 million -19.7%N/A1.4 $4.47 5/31/20221,320,000 shares $8.40 million +777.7%N/A2.1 $6.36 5/15/2022150,400 shares $594,080.00 +9.6%N/A0.9 $3.95 4/30/2022137,200 shares $429,436.00 -14.7%N/A1.9 $3.13 4/15/2022160,800 shares $520,992.00 -7.8%N/A2.2 $3.24 3/31/2022174,300 shares $587,391.00 -3.7%N/A2.3 $3.37 3/15/2022180,900 shares $510,138.00 -22.8%N/A1.9 $2.82 2/28/2022234,200 shares $702,600.00 -9.1%N/A2 $3.00 2/15/2022257,600 shares $801,136.00 -26.0%N/A2 $3.11 1/31/2022348,200 shares $1.06 million +10.2%N/A1.9 $3.03 1/15/2022316,100 shares $995,715.00 -3.1%N/A0.4 $3.15 12/31/2021326,100 shares $1.03 million -51.6%N/A0.4 $3.15 12/15/2021674,000 shares $2.37 million -27.9%N/A0.8 $3.51 11/30/2021934,400 shares $3.16 million -16.6%N/A1.2 $3.38 11/15/20211,120,000 shares $4.49 million +118.9%N/A1.4 $4.01 10/29/2021511,600 shares $1.40 million -4.0%N/A0.7 $2.74 10/15/2021532,900 shares $1.53 million -4.1%1.7%6.3 $2.88 9/30/2021555,900 shares $1.82 million -15.2%1.8%6.2 $3.27 9/15/2021655,800 shares $2.26 million +5.6%2.1%3.6 $3.45 8/31/2021621,300 shares $2.35 million -3.6%2.0%2.9 $3.79 8/13/2021644,200 shares $2.15 million -10.8%2.1%2.8 $3.33 7/30/2021722,000 shares $2.40 million +2.2%2.4%2.9 $3.33 7/15/2021706,400 shares $2.53 million +15.3%2.4%2.5 $3.58 6/30/2021612,700 shares $2.59 million -54.6%2.1%2 $4.22Healthcare Takes A Big Step Forward With The Help Of AI (Ad)The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.Click here to see why this small company is trusted by the Mayo Clinic CNCE Short Interest - Frequently Asked Questions What is Concert Pharmaceuticals' current short interest? Short interest is the volume of Concert Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of February 15th, investors have sold 1,080,000 shares of CNCE short. Learn More on Concert Pharmaceuticals' current short interest. What is a good short interest ratio for Concert Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CNCE shares currently have a short interest ratio of 1.0. Learn More on Concert Pharmaceuticals's short interest ratio. Which institutional investors are shorting Concert Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Concert Pharmaceuticals: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Concert Pharmaceuticals' short interest increasing or decreasing? Concert Pharmaceuticals saw a decline in short interest during the month of February. As of February 15th, there was short interest totaling 1,080,000 shares, a decline of 58.5% from the previous total of 2,600,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Concert Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Concert Pharmaceuticals: Adlai Nortye Ltd. (0.02%), Atai Life Sciences (4.81%), ADC Therapeutics SA (1.81%), Corbus Pharmaceuticals Holdings, Inc. (4.58%), PepGen Inc. (1.48%), Mereo BioPharma Group plc (1.86%), Organogenesis Holdings Inc. (9.35%), Neoleukin Therapeutics, Inc. (0.35%), Heron Therapeutics, Inc. (17.00%), Shattuck Labs, Inc. (4.40%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Enbridge Inc. ($4.09 billion), Occidental Petroleum Co. ($3.00 billion), T. Rowe Price Group, Inc. ($2.35 billion), Coinbase Global, Inc. ($2.30 billion), Paramount Global ($2.04 billion), Etsy, Inc. ($1.90 billion), Voya Financial, Inc. ($1.77 billion), CarMax, Inc. ($1.67 billion), Royal Caribbean Cruises Ltd. ($1.58 billion), and Monolithic Power Systems, Inc. ($1.47 billion). View all of the most shorted stocks. What does it mean to sell short Concert Pharmaceuticals stock? Short selling CNCE is an investing strategy that aims to generate trading profit from Concert Pharmaceuticals as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Concert Pharmaceuticals? A short squeeze for Concert Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CNCE, which in turn drives the price of the stock up even further. How often is Concert Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CNCE, twice per month. The most recent reporting period available is February, 15 2023. More Short Interest Resources from MarketBeat Related Companies: Adlai Nortye Short Interest Atai Life Sciences Short Interest ADC Therapeutics Short Interest Corbus Pharmaceuticals Short Interest PepGen Short Interest Mereo BioPharma Group Short Interest Organogenesis Short Interest Neoleukin Therapeutics Short Interest Heron Therapeutics Short Interest Shattuck Labs Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CNCE) was last updated on 4/17/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsOptions trading has suddenly become more reliable.Eagle PublishingTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsThe #1 Crypto for 2024InvestorPlaceThe Greatest Bull Market in Crypto History…Weiss RatingsA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics